The specific goals are:
A. study of mechanisms and treatment of cancer and infectious diseases;
B. establishment of national platform for chemical biology and drug design;
C. identification of new targets, biomarkers and diagnostic approaches leading to individualized therapy;
To achieve its goals, the BIOMEDREG will take advantage of the close links with the Project Partners: i) the major regional hospital – the University Hospital in Olomouc (UHO, thereby providing direct access to clinical material and potential clinical trials), and ii) the internationally highly competitive Czech chemistry and biochemistry centers: Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) and Institute of Chemical Technology Prague (ICT), which will directly participate in the Project, and are highly complementary to the mission of the BIOMEDREG, providing unique compound libraries and know-how for the BIOMEDREG Centre in Olomouc and the unifying focus on biological chemistry applied to pathogenetic pathways and drug discovery. The BIOMEDREG infrastructure will be joined workplace of the four institutions located in the eligible region of the Czech Republic (Olomouc), and within an easy reach of the major biomedical and chemical campuses in the country.

Primary objective

To establish a new institute (Institute of Molecular and Translational Medicine at Faculty of Medicine and Dentistry, Palacký University in Olomouc), technological infrastructure and platform for molecularly-oriented basic and translational biomedical research, aiming at better understanding of molecular bases of cancer and infectious diseases, leading to discovery of new biomarkers and therapeutic targets, followed by validation of biological activities of small molecules identified in high-throughput screening,  preclinical testing and proof-of concept clinical trials. Infrastructural part of the project will concentrate in common platform individual core facilities with unique technologies, and will consist of 5 core facilities (Bioinformatics and Biostatistics, Animal Models, Genomics, Proteomics and Cell Biology Core Facility) that provide key technical services to Applicant, Partners and external users.

Secondary objectives

To establish a network encompassing top-level research groups in biomedicine and translational medicine, chemical biology and medicinal chemistry;
1. To enhance and expand the capabilities of the Palacky University to serve as a major regional referral resource for advanced medical diagnostics, prevention and therapy;
2. To integrate Central Moravian and Czech scientists into top-level research consortium;
3. To improve technological platforms of science in the Czech Republic;
4. To bring together experts in molecular sciences and translational medicine;
5. To educate pre- and postgraduate students and to attract young investigators by providing an intellectually and technologically highly stimulating environment;
6. To offer expertise for biotechnological, chemical and pharmaceutical industry and to create opportunities for development of innovative companies in the region;
7. To further promote the existing collaborations and integration within European and global research initiatives.
The main end users will be the scientific community, students, biopharmaceutical and health care industry and patients.

List of research programmes:
1. Molecular basis of diseases and molecular targets
2. Medicinal chemistry
3. Chemical biology and experimental therapeutics
4. Biomarkers - identification and validation
5. Pharmacology and Toxicology
6. Translational medicine

Milestones and expected results:
: Start of the project (04/2010), Tenders and purchase of investments (04/2010-11/2013), IMTM building development (09/2010-12/2012), Start of research programs (04/2010), Final building approval (12/2012), Start-up of research works at the IMTM building (01/2013), End of the project (03/2014), Start of the monitoring period (04/2014), End of the monitoring period (03/2019).
Expected results: Proposed project will provide unique information on pathways and molecules acting as barriers against cancer, their deregulation during tumorigenesis, infectious diseases, disease resistance to current therapies, etc. It will further identify drugable targets and provide a unique platform for identification of novel chemical entities with potential use as structural motifs for new drugs. The detailed biological understanding of molecular pathologies will further promote the development of unprecedented diagnostic, prognostic, and therapeutic strategies.